To evaluate the clinical efficacy and safety of the domestic SR-ENS-600 single-port laparoendoscopic surgical robot system combined with the enhanced recovery after surgery (ERAS) protocol in the treatment of benign gynecological diseases such as ovarian cysts, uterine fibroids, and cervical intraepithelial neoplasia.

A single-arm study was conducted, enrolling 44 patients with benign gynecological diseases who underwent surgery at the Department of Obstetrics and Gynecology, Peking Union Medical College Hospital from Jan. 2023 to Oct. 2025. All patients underwent single-port laparoscopic surgery (including single-port robotic ovarian cystectomy/adnexectomy, myomectomy, and total hysterectomy) using the SR-ENS-600 system, with standardized perioperative ERAS management. The surgical success rate, multiple perioperative parameters (operative time, intraoperative blood loss, time to first flatus, postoperative hospital stay), numerical rating scale (NRS) pain scores, and adverse events were recorded and compared with literature data of the da Vinci SP single-port surgical robot system.

The surgical success rate was100% with no conversion to laparotomy or multi-port laparoscopic surgery. The operative time and intraoperative blood loss in the single-port robotic ovarian cystectomy/adnexectomy (SRC) group, single-port robotic myomectomy (SRM) group, and the overall cohort were lower than those reported for the corresponding procedures with the da Vinci SP system. For the single-port robotic total hysterectomy (SRH) group, the operative time and blood loss were slightly higher than those of the da Vinci SP system, but the difference was not statistically significant. For all patients, the mean time to first flatus was 20.97±6.23 h, and the mean postoperative hospital stay was 2.86±1.66 d, both significantly shorter than those of the da Vinci SP system (34.1±15.5 h and 4.6±0.7 d, respectively). Pain control was excellent: the median NRS pain score was 3.00 (2.00, 3.75) at 6 h postoperatively and decreased to 1.00 (0.00, 1.00) at 24 h postoperatively, with no need for additional analgesic drugs. During the study period, there were no serious adverse events or complications.

The domestic SR-ENS-600 single-port laparoendoscopic surgical robot system combined with the ERAS protocol is safe and effective in the treatment of benign gynecological diseases, comparable to that of imported similar robotic systems, and it is more competitive in terms of recovery efficiency and cost-effectiveness, showing promising potential for clinical application and promotion.